NORTHERN-DATA-AG
30.3.2020 08:44:06 CEST | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, today reports that the Corona Virus / COVID-19 -Pandemic is resulting in a massive increase in computing capacity demand. In order to meet the increased demand, the company has instigated an acceleration of the expansion of capacities at its locations and in addition is looking to develop further locations.
Immediate demand for computing power in the wake of the pandemic is being driven by two immediate and game changing developments: Firstly, pharmaceutical companies and research institutions worldwide are using HPC systems on a large scale for the first time in order to carry out calculations and simulations in the field of bioinformatics and epidemiology in the shortest possible time, which with conventional computer systems can take several months or even years. This gives research teams the opportunity to accelerate the development of novel drugs that can be used against the coronavirus in the short term. Northern Data management expects this trend to continue after the end of the COVID 19 pandemic.
Secondly working conditions worldwide have shifted drastically online in a matter of weeks through the course of the COVID 19 pandemic, this has led to a massive increase in demand for computing capacity. Due to the current restrictions, many companies in parts of the United States, Europe and Asia are forced to operate with an almost 100% home office ratio. The associated use of digital applications such as video conferencing tools is causing an explosion in demand for data capacities. Also, this trend will continue beyond the corona crisis.
Northern Data will start operating its newest HPC facility in the United States in the coming days. The world's largest HPC data center is being built in Texas on an area of more than 100 acres, which corresponds to the size of around 57 soccer fields. The company originally intended to achieve a total capacity of one gigawatt at the US location by the end of the year. Due to the changed and overwhelming demand situation, plans are now beginning to seamlessly expand the location to up to 3.6 gigawatts.
The company is also accelerating the development of additional locations for additional large-scale HPC facilities in Canada and Scandinavia.
"We are facing overwhelming demand," said Aroosh Thillainathan, CEO of Northern Data AG. "In some areas we see a thirty times higher market demand than we can build up capacities by the end of the year. We now benefit from our many years of experience in large-scale high-performance computing in order to further accelerate ongoing scaling."
Northern Data published its forecast for 2020 on March 16. Based on current expectations and in line with contracts already signed, the Management Board expects revenues of EUR 120 million to EUR 140 million in the course of 2020. Accordingly, the Management Board expects EBITDA of between EUR 45 million and EUR 60 million. This guidance is based only on a partial utilization of initially 30% of the 1GW expansion stage, based on already concluded contracts for the provision of HPC solutions with global customers. The forecast will be adjusted in due course as new customer acquisition progresses.
About Northern Data:
Northern Data AG develops and builds global infrastructure solutions in the area of high-performance computing (HPC). The company offers solutions in areas such as machine learning and artificial intelligence, big data analytics, blockchain, game streaming and others. The international company emerged from the merger of the German Northern Bitcoin AG and the American Whinstone US, Inc. and is today a recognized market leader in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both stationary in large, state-of-the-art data centers and in mobile, high-tech data centers based on containers, which can be set up at any location worldwide. It combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. In Texas, Whinstone is currently building the largest HPC data center in the United States and the largest facility in the world specifically for HPC applications.
| Language: | English |
| Company: | Northern Data AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate |
| Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200329005043/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
